Achieve Life Sciences Announces Granting of New Hire Inducement Awards
MWN-AI** Summary
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a specialty pharmaceutical firm based in Seattle and Vancouver, announced on October 1, 2025, the approval of stock option grants for five new employees under its 2024 Equity Inducement Plan. The board of directors has authorized an aggregate of 161,000 stock options, which can be exercised at the closing price of Achieve's common stock on the grant date and will vest incrementally over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4), signifying its role in attracting talent as the company progresses in its mission.
Achieve Life Sciences focuses on the global market for smoking cessation and nicotine dependence treatment through its lead investigational product, cytisinicline. The company is at a critical juncture, with its New Drug Application (NDA) accepted by the U.S. Food and Drug Administration (FDA) in June 2025 for the treatment of nicotine dependence, carrying a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. Cytisinicline has shown promise in Phase 3 studies and has been designated as a "Breakthrough Therapy" by the FDA for its potential to address the pressing need for effective smoking cessation aids.
With approximately 29 million adults in the United States smoking combustible cigarettes and a growing number turning to e-cigarettes, Achieve's cytisinicline could play a significant role in combating nicotine addiction. The drug's unique mechanism targets nicotinic acetylcholine receptors in the brain, helping to mitigate cravings and reduce the satisfaction associated with nicotine. Presently, there are no FDA-approved treatments for e-cigarette cessation, highlighting the critical demand for effective interventions like cytisinicline in the fight against nicotine dependence.
MWN-AI** Analysis
Achieve Life Sciences, Inc. (Nasdaq: ACHV) is gaining momentum in the biotech arena with its innovative approach to treating nicotine dependence through cytisinicline. The recent announcement regarding stock option grants for new hires aligns with the company's strategy to bolster its talent pool ahead of pivotal FDA decisions. As of October 1, 2025, Achieve has approved option grants totaling 161,000 shares under its 2024 Equity Inducement Plan. This move not only incentivizes new employees but also indicates the company's confidence in its future prospects.
The company's recent submission of its New Drug Application (NDA) to the FDA for cytisinicline underscores its commitment to addressing the substantial market for smoking cessation. With a PDUFA date of June 20, 2026, and a successful history in Phase 3 studies, the risk-reward profile for investing in Achieve appears appealing, especially considering the lack of FDA-approved products specifically for e-cigarette cessation—a growing segment among adults and adolescents.
Investors should consider the larger context of Achieve's developments. The global smoking epidemic presents a critical opportunity, with millions seeking effective cessation aids. The introduction of cytisinicline could not only bolster Achieve’s revenue but also establish it as a frontrunner in this underserved market.
However, potential investors should remain cautious. Market dynamics, regulatory uncertainties, and competition in the pharmaceuticals space can impact stock performance. Closely monitor the upcoming developments, particularly the FDA decision in mid-2026, as this will be a decisive moment for Achieve Life Sciences. With growing public health concerns around nicotine dependence, the stock could offer considerable upside for those willing to navigate its inherent risks. It may be a strategic time to buy, depending on the overall market conditions and your investment strategy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achieve’s 2024 Equity Inducement Plan.
The stock options have an exercise price equal to the closing price of Achieve’s common stock on October 1, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to the employee’s continued service through each applicable vesting date.
The stock options are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).
About Achieve Life Sciences, Inc.
Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
About Cytisinicline
There are approximately 29 million adults in the United States who smoke combustible cigarettes. 1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. 2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. 3
In addition, there are approximately 17 million adults in the United States who use e-cigarettes, also known as vaping. 4 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes. 5 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address this critical unmet need.
Cytisinicline is a plant-derived alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking cessation and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is a new investigational product candidate being developed for the treatment of nicotine dependence for smoking cessation and has not been approved by the Food and Drug Administration for any indication in the United States.
Achieve Contact
Nicole Jones
Vice President, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
425-686-1510
References
1 VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641.
2 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
3 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
4 Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic cigarette use among adults in the United States, 2019–2023. NCHS Data Brief, no 524. Hyattsville, MD: National Center for Health Statistics. 2025. DOI: https://dx.doi.org/ 10.15620/cdc/174583.
5 Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.
FAQ**
How might the development and commercialization of Achieve Life Sciences Inc. ACHV's cytisinicline impact smoking cessation rates in Seattle and Vancouver, given the prevalence of smoking in these cities?
What regulatory challenges could Achieve Life Sciences Inc. ACHV face when seeking FDA approval for cytisinicline in addressing nicotine dependence in both Seattle and Vancouver?
In what ways could Achieve Life Sciences Inc. ACHV's upcoming PDUFA date of June 20, 2026, influence local healthcare policies in Seattle and Vancouver regarding smoking cessation programs?
How is public perception of smoking and vaping in Seattle and Vancouver likely to influence the market potential for Achieve Life Sciences Inc. ACHV’s cytisinicline if it gains approval?
**MWN-AI FAQ is based on asking OpenAI questions about Achieve Life Sciences Inc. (NASDAQ: ACHV).
NASDAQ: ACHV
ACHV Trading
-0.81% G/L:
$4.31 Last:
165,973 Volume:
$4.28 Open:
